drugset
drugset / Trial / NCT05839470

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

NCT05839470 ↗

Phase 2 Unknown 20 enrolled Fujian Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors. This was a phase II study of cadonilimab in combination with bevacizumab and FOLFOXIRI as first line therapy for metastatic microsatellite stable (MSS) colorectal cancer. The goal of this clinical trial is to evaluated the efficacy and safety.

Timeline

Start
2023-11-19
Primary completion
2024-03-01
Completion
2025-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 6 mg/kg Intravenous
Background Irinotecan Small molecule 165 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Levoleucovorin Unknown 200 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

colorectal cancer